This study is a randomized, controlled, open-label, phase II clinical study. This study is designed to evaluate the efficacy and safety of second-line standard treatment sequential TAS-102 and bevacizumab combined with local treatment versus continuous treatment of standard second-line therapy in advanced colorectal cancer.
Unresectable colorectal adenocarcinoma confirmed by histopathology or cytology;
Patients who have failed first-line standard therapy and are intended to receive second-line standard therapy;
At least one measurable lesion according to RECIST 1.1 criteria;
ECOG Performance Status 0-1;
Allergy to the investigational drug and/or its excipients;
Pregnant or lactating women;
Prior treatment with TAS-102;
Any CTCAE grade 2 or above toxicity caused by previous treatment that has not yet subsided (excluding alopecia, skin pigmentation, and chemotherapy-induced neurotoxicity);